Anest. intenziv. Med. 2006;17(2):78-81

What's new in the pharmacotherapy of pain?Algeziology

New developments in the pharmacotherapy of pain have brought both new drugs and new delivery forms of already established substances.
The aim of the development of new drugs is first of all reducing the occurrence of undesirable side effects, an increase in efficiency and more comfortable modes of application.
The new opioid formulas include controlled-release hydromorfon, matrix transdermal delivery of fentanyl and Ionsys transdermal fentanyl for treatment of acute postoperative pain.
Ionsys combines fixed background delivery of fentanyl and patient-controlled bolus administration of rapidly absorbing fentanyl. Ionsys will be the first application system of its kind on the market.
Our choice of anticonvulsants grew with the new medication Pregabalin (brand name Lyrica) in 2005.We will probably encounter a new, true analgesic antidepressant next year. In the field of neuromodulation there is a continuing trend of miniaturization and prolonging the lifespan of devices.Two of the leading manufacturers of these devices introduced their new products at the 7th INS World Congress in Rome. Medtronic introduced a rechargeable neurostimulator Revita and a new programmable SynchroMed pump. ANS introduced their Renew neurostimulator (radio-frequency (RF) system) using an external power source.

Keywords: hydromorphon; fentanyl; Ionsys; pregabalin; duloxetin; neuromodulation

Published: April 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
What's new in the pharmacotherapy of pain? Anest. intenziv. Med. 2006;17(2):78-81.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Hagen, N. A., Thirlwell, M. P., Dhaliwal, H. S. et al. Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled release hydromorphone. J. Clin. Pharmacol., 1995, 35, p. 37-44. Go to original source... Go to PubMed...
    2. Moriarty, M., McDonald, C. J., Miller, A. J. A randomised crossover comparison of controlled release hydromorphone tablets with controlled relea morphine tablets in patients with cancer pain. J. Clin. Res., 1999, 2, p. 1-8.
    3. Hennies, H. H., Friderichs, E., Schneider, J. Receptor binding, analgesic and antitussive potency of tramadol and other selected opioids. Arzneim-Forsch/Drug Res., 1988, 38, p. 877-880.
    4. Jaffe, J. H., Martin, W. R. Opioid analgesics and antagonists. In Goodmann, G. A., Godmann, L. S., Rall, T. W., Murad, F. (eds) The Pharmacological basis of Therapeutics. 7th ed. New York : MacMillan 1985, p. 491-531.
    5. Quigley, C. Hydromorphone for acute and chronic pain. Cochrane database Syst. Rev., 2002, 3447. Go to original source... Go to PubMed...
    6. Sitting, H. Sustained-release hydromorphone reduces severe pain and improves quality of life. MMW-Fortschr. Med., 2004, p. 3-4, 95-98.
    7. Sohn, W. Hydromorphon - ein starkes Opioid mit Vorteilen bei der Verstoffwechselung. Fortschritte der Medizin, 2003, 121, s. 51-55.
    8. Hanks, G. W., Wand, P. J. Enterohepatic circulation of opioid drugs. It is clinically relevant in the treatment of cancer patients. Clin. Pharmacokinet., 1989, 17, p. 65-68. Go to original source... Go to PubMed...
    9. Sitting H. Sustained-release hydromorphone reduces severe pain and improves quality of life. MMW-Fortschr. Med., 2004, s. 3-4, 95-98.
    10. Allan, L., Hays, H., Jensen, N. H. et al. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine by treating chronic non-cancer pain. BMJ, 2001, 322, p. 1154-1158. Go to original source... Go to PubMed...
    11. Clark, A. J., Ahmedzai, S. H., Allan, L. G. et al. Efficacy and safety of transdermal fentanyl and sustaned-release oral morphine in patients with cancer and chronic non-cancer pain. Curr. Med. Res. Opin., 2004, 20, p. 1419-1428. Go to original source... Go to PubMed...
    12. Clark, A. J., Allan, L. G., Horbay, G. L. A. et al. Transdermal fentanyl (TDF) is significantly better than sustained release morphine (SRM) in managing chronic pain: a meta-analysis in cancer and in chronic non-cancer pain. J. Pain, 2004, 5, S1.
    13. Newshan, G., Lefkowitz, M. Transdermal fentanyl for chronic pain in AIDS: a pilot study. J. Pain Symprom Manage., 2001, 21, p. 69-77. Go to original source... Go to PubMed...
    14. Dizdar, Y, Kucucuk, S, Kaytan, E et al. Evaluation of the clinical efficacy of transdermal fentanyl (Durogesic) in adults with cancer-related pain: an open multicentre study, on behalf of Durogesic Mewa Working Group. Pain in Europe IV - 4th Congress of the European Federation of IASP Chapters (EFIC), Prague, 2003, 300.
    15. van Seventer, R., Smit, J., Schipper, R. et al. Comparison of TTS fentanyl with sustained-released oral morphine in the treatment of patients not using opioids for mild-to-moderate pain. Curr. Med. Res. Opin., 2003, 19, p. 457-469. Go to original source... Go to PubMed...
    16. Donner, B., Zenz, M., Tryba, M. et al. Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain. J. Pain, 1996, 64, p. 527-534. Go to original source... Go to PubMed...
    17. Langford, R., Ratcliffe, S., McKenna, F., Sevcik, P., Szechinski, J., Vojtassak J. Effects of transdermal fentanyl on pain and functioning in osteoarthritis: a randomized, double-blind, placebo-controlled trial. Pain Practice, Book of Abstracts, 2004, 285 p. Go to original source...
    18. Menten, J., Desmedt, M., Lossignol, D., Mulllie, A. Longitudinal follow-up of TTS-fentanyl in patients with cancer related pain: results of a compassionate-use study with special focus on elderly patients. Cur. Med. Opin., 2002, 178, p. 488-498. Go to original source... Go to PubMed...
    19. Sohn, W. Hydromorphon - ein starkes Opioid mit Vorteilen bei der Verstoffwechselung. Fortschritte der Medizin, 2003, 121, s. 51-55.
    20. Mystakidou, K., Parpa, E., Tsililka, E. et al. Long-term management of noncancer pain with transdermal therapeutic system-fentanyl. J. Pain, 2003, 4, p. 298-306. Go to original source... Go to PubMed...
    21. Freynhagen, R. Switching from Reservoir to Matrix Systems for the Transdermal Delivery of Fentanyl: A Prospective, Multicenter Pilot Study in Outpatients with Chronic Pain. J. Pain Symptom Manage., 2005, 30, 3, p. 289-297. Go to original source... Go to PubMed...
    22. Sinatra, R. The fentanyl HCl patient-controlled transdermal system (PCTS): an alternative to intravenous patient-controlled analgesia in the postoperative setting. Clin. Pharmacokinet., 2005, 44, Suppl 1, p. 1-6. Go to original source... Go to PubMed...
    23. Bailer, M., Johannessen, S. I., Kupfeberg, H. J. et al. Progress report on new antiepileptic drugs: a summary of the Fourth Eilat Conference (EILAT IV). Epilepsy Res., 1999, 34, p. 1-41. Go to original source... Go to PubMed...
    24. Hindmarch, I., Trick, L., Ridout, F.A. A double-blind, placebo- and positive-internal-controlled (alprazolam) investigation of the cognitive and psychomotor profile of pregabalin in healthy volunteers. 2005, 183, 2, p. 133-143. Go to original source...
    25. Zareba, G. Pregabalin: a new agent for the treatment of neuropathic pain. Drugs Today, 2005, 41, 8, p. 509-516. Go to original source... Go to PubMed...
    26. Sabatowski, R., Gálvez, R., Cherry, D. A. et al. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain, 2004, 109, p. 26-35. Go to original source... Go to PubMed...
    27. Doležal, T. Postavení pregabalinu v terapii neuropatické bolesti. Bolest, 2005, 8, s. 16.
    28. Goldstein, A., Lub, Y., Detkeb, M., Leeb, T., Iyengarb, S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain, 2005, 116, p. 109-118. Go to original source... Go to PubMed...
    29. Hassenbusch, S. J., Poctenou, R. K., Cousins, M. et al. Polyanalgesic Consensus Conference 2003: an update of the management of pain by intraspinal drug delivery - report of an expert panel. J. Pain Symptom Manage., 2004, 27, p. 540-563. Go to original source... Go to PubMed...
    30. PRIALT (package insert). San Diego, Calif: Elan Pharmaceuticals, Inc. 2004.
    31. Hrazdilová, O., Šerý, O., Pitelová, R., Ševčík, P. Vztah mezi M235T polymorfizmem pro angiotenzinogen a inzerčním/delečním polymorfizmem pro angiotenzinogen-konvertující enzym a vnímání akutní bolesti. Bolest, 2005, 8, s. 18-19.

    Return to the content


    Anesteziologie a intenzivní medicína

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.